Research PaperJournal of Pharmacology and PharmacotherapeuticsVol. 3 | Issue 2 | 2012 | pp. 143–148Open access
Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model
- 2*,
- 2,
- 2,3,
- ,
- ,
- 2,
- 2
- 1 Laboratory of Pharmacology and Experimental Therapeutics, IBILI, Medicine Faculty, Coimbra University.
- 2 Department of Urology and Renal Transplantation, Coimbra University Hospital.
- 3 Center for Neuroscience and Cell Biology, Coimbra, Portugal Research Paper.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: José Sereno
Department of Urology and Renal Transplantation, Coimbra University Hospital.
Copyright: © 2012 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2012
How to cite
Sereno, J., Romão, A. M., Parada, B., Lopes, P., Carvalho, E., Teixeira, F., & Reis, F. (2012). Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model. Journal of Pharmacology and Pharmacotherapeutics, 3(2), 143–148. https://doi.org/10.4103/0976-500X.95513
Abstract
Objective: To compare the cardiorenal effects of early versus late cyclosporine (CsA) to sirolimus (SRL) conversion, using a novel animal model that mimics these protocols used in the clinical practice, and focusing on blood pressure, heart rate (HR), biochemical data and heart and kidney lipid peroxidation. Materials and Methods: The study had five groups. Six male Wistar rats in each group were used during a 9-week study protocol: control, CsA (5 mg/kg/day), SRL (1 mg/kg/day); early conversion and late conversion. Cardiorenal evaluation was assessed by biochemical data, blood pressure, HR, and heart and kidney lipid peroxidation. Results: As expected, CsA promoted cardiorenal impairment, viewed by development of hypertension, tachycardia, increased urea, creatine kinase, and glucose levels, as well as heart and kidney oxidative stress. SRL, as expected, promoted less cardiorenal side effects, namely those related with nephrotoxicity. In agreement, both early and late conversions from CsA to SRL produced less side-effects, namely those related to the CsA-induced nephrotoxicity. Conclusions: In our model, both early and late CsA to SRL conversion promoted amelioration of the CsA -induced cardiorenal damage. However, early substitution seems to produce more benefits, in particular due to higher improvement of the cardiac profile.
Keywords
Subject
Article metadata
| Title | Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model |
|---|---|
| Authors | José Sereno; Ana M. Romão; Belmiro Parada; Patrícia Lopes; Eugénia Carvalho; Frederico Teixeira; Flávio Reis |
| Affiliations | Laboratory of Pharmacology and Experimental Therapeutics, IBILI, Medicine Faculty, Coimbra University.; Department of Urology and Renal Transplantation, Coimbra University Hospital.; Center for Neuroscience and Cell Biology, Coimbra, Portugal Research Paper. |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 3, Issue 2 (2012) |
Also in this issue
- Clinical trial ethics in India: One step forward, two steps backpp. 95–97
- Pharmacotherapy for multidrug resistant tuberculosispp. 98–104
- A review of antihistamines used during pregnancypp. 105–108
- Ulipristal acetate, a progesterone receptor modulator for emergency contraceptionpp. 109–111
- Epilepsy: Novel therapeutic targetspp. 112–117
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026